IGF-1 LR3 Protocol: Complete Cycling & Dosing Guide
Disclaimer: This guide is educational content for research purposes only and does not constitute medical advice. IGF-1 LR3 is not approved for human use in any jurisdiction and is classified as a research chemical. Consult with a qualified healthcare provider before use. The following information is based on compound data and should not be interpreted as a recommendation to use this substance.
Overview
IGF-1 LR3 is a synthetic peptide analog of insulin-like growth factor 1, featuring a 13-amino acid N-terminal extension and arginine substitution at position 3. These modifications extend its half-life to 20–30 hours compared to native IGF-1's 12–15 minutes, and critically reduce its binding affinity for IGF-binding proteins (IGFBPs). This means a significantly higher proportion of circulating IGF-1 LR3 remains free and biologically active in peripheral tissues.
The compound activates the IGF-1 receptor (IGF-1R), triggering downstream PI3K/Akt/mTOR and MAPK/ERK signaling cascades that drive protein synthesis, satellite cell activation, and myofibrillar growth. At higher concentrations, it also cross-reacts with insulin receptors, stimulating glucose uptake and creating acute hypoglycemia risk—the most common acute adverse effect users encounter.
Typical dosing ranges from 20–100 mcg injected once daily. The extended half-life permits once-daily administration, distinguishing it from native IGF-1, which requires multiple daily injections. Cycling is essential to prevent receptor desensitization and reduce theoretical oncogenic risk from prolonged mitogenic signaling.
Standard Protocol
Dosing Range and Frequency
- Beginner dose: 20–40 mcg once daily
- Intermediate dose: 40–60 mcg once daily
- Advanced dose: 60–100 mcg once daily
- Frequency: Once daily via subcutaneous injection
- Injection timing: Post-workout or with a meal (to mitigate hypoglycemia risk)
Cycle Structure
Standard 40-day on / 20-day off cycle:
- Week 1–2: Dose escalation phase (start at 20–30 mcg, increase by 10 mcg every 2–3 days)
- Week 3–5: Maintenance at target dose
- Week 6: Final week at target dose, then begin 20-day cessation
- Days off: Full 20-day break with zero IGF-1 LR3 administration
Rationale: The 20-day off-period allows receptor sensitivity to recover and reduces the risk of chronic receptor downregulation. This structure also provides a window to assess baseline physiology and recover from any accumulated side effects.
Dose Escalation Strategy
Begin conservatively. Even experienced users should avoid jumping directly to 80–100 mcg:
- Day 1–2: 20 mcg daily
- Day 3–4: 30 mcg daily
- Day 5–6: 40 mcg daily
- Day 7+: Target dose (typically 50–80 mcg for intermediate users)
This tiered approach allows you to assess individual hypoglycemia sensitivity and gauge localized injection site responses before committing to higher doses. Rapid escalation increases acute hypoglycemia risk and makes it difficult to identify which dose produces unwanted side effects.
Goal-Specific Protocols
Protocol A: Muscle Hypertrophy Focus
Cycle: 40 days on, 20 days off
Dose: 60–100 mcg daily
Timing: Post-workout injection
Training frequency: 5–6 days per week (split routine recommended)
Nutrition: Elevated protein (1.0–1.2 g per pound of body weight) and caloric surplus
Rationale: Higher doses and post-workout timing coincide with elevated insulin sensitivity and nutrient uptake. The extended half-life ensures IGF-1 LR3 is active during the entire post-workout anabolic window. Satellite cell activation and protein synthesis are maximized when training volume is high.
Dietary integration: Inject immediately after training, then consume a carbohydrate-rich meal (60–80 g carbs) within 30 minutes to prevent post-injection hypoglycemia and drive nutrient partitioning toward muscle.
Protocol B: Body Recomposition (Lean Gain)
Cycle: 40 days on, 20 days off
Dose: 40–60 mcg daily
Timing: Morning injection with breakfast
Training frequency: 4–5 days per week (mixed strength and conditioning)
Nutrition: Maintenance calories with moderate protein (0.8–1.0 g per pound)
Rationale: Moderate dosing with consistent morning timing simplifies adherence and reduces acute hypoglycemia risk. Lower total volume is sufficient for recomposition because IGF-1 LR3's anti-catabolic properties preserve muscle during fat loss phases. The morning injection, paired with carbohydrate intake, stabilizes blood glucose throughout the day.
Key principle: At this dose, fat loss is primarily driven by training intensity and caloric deficit; IGF-1 LR3 serves as a preservation agent rather than a primary driver.
Protocol C: Injury Recovery and Soft Tissue Repair
Cycle: 30 days on, 30 days off (extended rest reduces soft tissue overgrowth)
Dose: 30–50 mcg daily
Timing: Daily, preferably evening or before sleep
Training frequency: 2–3 days per week (non-compete movement only)
Nutrition: Adequate protein (0.8–1.0 g per pound) and micronutrient density (prioritize mineral intake)
Rationale: Compound data indicates IGF-1 LR3 promotes nerve regeneration and volumetric muscle restoration in animal models. Lower dosing reduces risk of joint pain or acromegalic soft tissue changes. The extended off-period prevents cumulative cartilage and connective tissue hypertrophy, which can become painful with prolonged use.
Recovery protocol: Coordinate with physical therapy. Inject in the evening when inflammation is typically highest. Ensure adequate sleep and consider anti-inflammatory adjuncts (NSAIDs during the first 10–15 days if pain management is required).
How to Administer: Step-by-Step
Preparation and Reconstitution
-
Obtain supplies: Sterile syringe (29–31 gauge, 1 mL), bacteriostatic water (if lyophilized powder), alcohol wipes, sharps container, and the IGF-1 LR3 vial.
-
Inspect the vial: If powder, it should be white or off-white. If liquid, it should be clear. Discard if discolored or contains visible particles.
-
Reconstitute (powder form):
- Swab the rubber stopper with an alcohol wipe.
- Draw bacteriostatic water into a syringe (typically 1 mL per 1 mg vial, but check label).
- Inject water slowly into the vial, angling the needle to allow the stream to run down the vial wall (minimizes foaming).
- Let stand for 2–3 minutes; do not shake vigorously.
- The solution should be clear. If cloudy, discard.
-
Storage post-reconstitution: Refrigerate at 2–8°C (do not freeze). Reconstituted IGF-1 LR3 remains stable for up to 3 weeks if kept sterile.
Injection Procedure
-
Preparation: Wash hands thoroughly. Gather all materials on a clean surface.
-
Site selection: Choose a subcutaneous site—abdominal wall (pinch skin away from abdomen), outer thigh, or upper arm. Rotate sites daily to prevent lipodystrophy and localized edema.
-
Dose measurement:
- Draw the calculated volume into the syringe. Typical concentration is 100 mcg/mL, so a 50 mcg dose requires 0.5 mL.
- Verify the dose by reading the plunger position at eye level.
-
Injection:
- Swab the injection site with an alcohol wipe and allow to air-dry (5 seconds).
- Pinch the skin with one hand.
- Insert the needle at a 45–90° angle, depending on subcutaneous fat depth. Most users pinch and inject at 45° for comfort.
- Depress the plunger steadily (1–2 seconds per 0.5 mL).
- Withdraw the needle and apply light pressure with a clean tissue for 5 seconds if bleeding occurs.
-
Post-injection: Dispose of the needle in a sharps container. Do not recap the needle.
Timing and Food Intake
- Post-workout injection: Inject immediately after completing resistance training. Follow with a meal containing 60–80 g carbohydrate and 30–40 g protein within 30 minutes.
- Morning injection: Inject with breakfast to stabilize blood glucose and provide immediate nutrient availability.
- Evening injection: Inject 1–2 hours before bed if using for recovery; ensure you consume a light carbohydrate source (e.g., banana, 15–20 g carbs) 30 minutes post-injection to prevent nocturnal hypoglycemia.